Skip to main
SGRY

Surgery Partners (SGRY) Stock Forecast & Price Target

Surgery Partners (SGRY) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 38%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Surgery Partners is executing specific strategies to accelerate SS growth, with a focus on supporting and expanding services in surgical facilities in its existing markets. They are also investing in technology and recruiting for high-acuity specialties, positioning themselves as a more attractive and efficient alternative to traditional hospitals. Furthermore, divestiture of non-core assets and efficiency measures should improve cash conversion and increase margins, making Surgery Partners a strong value proposition for the US healthcare system.

Bears say

Surgery Partners is currently facing headwinds due to the impact of the COVID-19 pandemic on its business operations, with softer consolidated case volumes and higher staffing costs leading to margin pressure. Its recent divestiture of the Idaho Falls market is a positive step in its portfolio optimization strategy, but the company still faces challenges in meeting its previous targets for revenue and acquisitions. Additionally, the sustainability of the recent rebound in demand and patient volumes is uncertain, and the company will likely continue to face regulatory and reimbursement challenges.

Surgery Partners (SGRY) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 38% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Surgery Partners and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Surgery Partners (SGRY) Forecast

Analysts have given Surgery Partners (SGRY) a Buy based on their latest research and market trends.

According to 8 analysts, Surgery Partners (SGRY) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Surgery Partners (SGRY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.